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Themetabolicsyndrome(MS)andchronickidneydisease(CKD)havebothbecomeglobalpublichealthproblems,withincreasing
social and economic impact due to their high prevalence and remarkable impact on morbidity and mortality. The causality
between MS and CKD, and its clinical implications, still does remain not completely understood. Moreover, prophylactic and
therapeutic interventions do need to be properly investigated in this ﬁeld. Herein, we critically review the existing clinical evidence
that associates MS with renal disease and cardiovascular disease, as well as the associated pathophysiologic mechanisms and actual
treatment options.
1.Introduction
During the last decades, we have witnessed a global epidemic
of obesity [1]. A sedentary lifestyle and an atherogenic diet,
along with genetic predisposition, are probably the driving
forces of this problem. According to the last National Health
and Nutrition Examination Survey (NHANES), more than
one third of adult Americans are obese. The prevalence in
children and adolescents is also rising at an alarmingly rate
[2].
Obesity, particularly abdominal obesity, is associated
with resistance to the eﬀects of insulin on peripheral glucose
andfattyacidutilization.Theresultinghiperinsulinemiaand
hyperglycemia, as the release of adipocyte cytokines, have
been shown to induce vascular endothelial dysfunction, an
abnormal lipid proﬁle, hypertension, and vascular inﬂam-
mation, all of which are atherogenic [3–6]. The clustering
of metabolic cardiovascular risk factors, under a common
pathogenic process (insulin resistance),was described forthe
ﬁrst time in 1988 by Reaven [3], leading to the concept of
Metabolic Syndrome (MS). Since then, multiple deﬁnitions
have been made, all of them considering some combination
ofinsulinresistance,dyslipidemia(hypertriglyceridemia,low
HDL cholesterol), elevated fasting serum glucose, abdominal
obesity, and hypertension (Table 1)[ 7–11].
The MS aﬀects over 20% of adults in Western popula-
tions [12], and is becoming increasingly common [13–15],
inclusively in adolescents [16]. However, the prevalence of
MS varies widely according to geographic location, race,
gender, and urbanization. Since it was ﬁrst described, an
overwhelming body of evidence associated the MS with
subsequent development of type II diabetes mellitus and
cardiovasculardisease(CVD)[17–25].Recently,theevidence
associating MS with CVD has been synthesized in three
meta-analyses that showed an increased risk for incident
CVD (ranging from 53% to 118%) and all-cause mortality
(ranging from 27% to 60%) in subjects with MS [23–25].
This increased risk appears related to the risk factor cluster-
ing, rather than to obesity alone, as normal weight people
from the Framingham population meeting the criteria for
MS had a threefold increased risk for CVD, while obese
individuals withoutMSdid not havea signiﬁcantlyincreased
risk [26].
Additionally, especially in the last decade, a number of
other obesity-related disorders have been associated with the
MS, including: fatty liver disease, polycystic ovary syndrome,2 Cardiology Research and Practice
Table 1: Current deﬁnitions of the metabolic syndrome.
Parameters NCEP ATP3
(2005) [9]
IDF
(2005) [11]
EGIR
(1999) [8]
WHO
(1999) [7]
NHLBI/AHA
(2005) [10]
Required
Waist ≥ 94 cm
(men) or
≥80cm
(women)(a)
IR or fasting
hyperinsuline-
mia in top
25%
IR in top 25%(b);
glucose ≥
110mg/dL
(≥6.1mmol/L);
2-hr glucose
≥140mg/dL
(≥7.8mmol/L)
No. of
abnormalities
≥3o f : A n d≥2o f : A n d≥2o f : A n d≥2o f : ≥3o f :
Obesity Waist ≥102cm (men)
or ≥88cm (women)(c)
Waist ≥94 cm
(men) or
≥80cm
(women)
Waist/hip ratio
>0.9 (men) or 0.85
( w o m e n )o rB M I
≥30kg/m2
Waist ≥102cm (men) or
≥88cm (women)
Hypertension
≥130/85mmHg or
drug treatment
≥130/85mmHg
or drug
treatment
≥140/90mmHg
or drug
treatment
≥140/90mmHg
≥135/85mmHg or drug
treatment
Glucose
≥100mg/dL
(≥5.6mmol/L) or drug
treatment
≥100mg/dL
(≥5.6mmol/L)
or diagnosed
diabetes
110–125mg/dL
(6.1–
6.9mmol/L)
≥100mg/dL
(≥5.6mmol/L) or drug
treatment
HDL
cholesterol
<40mg/dL
(<1.0mmol/L) (men);
<50mg/dL
(<1.3mmol/L)
( w o m e n )o rd r u g
treatment
<40mg/dL
(<1.0mmol/L)
(men);
<50mg/dL
(<1.3mmol/L)
(women) or
drug treatment
<40mg/dL
(<1.0mmol/L)
<35mg/dL
(<0.9mmol/L)
(men); <40mg/dL
(<1.0mmol/L)
(women)
<40mg/dL
(<1.0mmol/L) (men);
<50mg/dL
(<1.3mmol/L) (women)
or drug treatment
Triglycerides
≥150mg/dL
(≥1.7mmol/L) or drug
treatment
≥150mg/dL
(≥1.7mmol/L)
or drug
treatment
≥180mg/dL
(≥2.0mmol/L)
or drug
treatment
≥150mg/dL
(≥1.7mmol/L)
≥150mg/dL
(≥1.7mmol/L) or drug
treatment
BMI: body mass index; EGIR: group for the study of insulin resistance; HDL: high-density lipoprotein; IDF: International Diabetes Federation; IR: insulin
resistance; NCEP: National Cholesterol Education Program; NHLBI/AHA: National Heart, Lung and Blood Institute/American Heart Association; WHO:
World Health Organization.
(a) South Asia and Chinese patients, waist ≥90cm (men) or ≥80cm (women); Japanese patients, waist ≥90cm (men) or ≥80cm (women).
(b) Insulin resistance measured using insulin clamp.
(c) Asian patients, waist ≥90cm (men) or ≥80 cm (women).
obstructive sleep apnea, hyperuricemia, and, in particular,
chronic kidney disease (CKD).
Chronic kidney disease is an important risk factor for
End-StageRenalDisease(ESRD),CVD,andprematuredeath
[27–31] and has become a global public health problem,
with increasing social and economic impact due to its high
prevalence [32, 33]. Indeed, almost 5% of adult Americans
have CKD but only a minority reach ESRD, suggesting that
most of these patients die of other causes, such as CVD
[26, 33, 34]. The possible association between MS and CKD,
in light of the growing epidemic of obesity, could represent a
windowofopportunity toidentifyindividualsatriskofCKD
(and, evidently, CVD) and to improve the burden of these
diseases through early detection and prevention.
Herein, we aim to critically review the existing clinical
evidence that associates MS with renal disease and CVD, as
well as the possible pathophysiologic mechanisms involved
and actual treatment options.
2.ChronicKidney Diseaseand
CardiovascularDisease
Chronic kidney disease is an independent risk factor for
CVD and all cause-mortality and is considered a coronary
heart disease risk equivalent [35–37]. In patients with CKD
stage 2 or higher, there is a direct relationship between
the degree of renal function impairment and cardiovascular
risk, independent of other known risk factors (age, blood
pressure, diabetes, and smoking), history of CVD, and
presence of proteinuria [36]. Even subtle reductions in renal
function, in apparently healthy persons, increase the risk of
cardiovascular morbidity and mortality [37, 38].
The main factors pointed out as responsible for this in-
creased risk include volume overload and anemia leading to
left ventricular hypertrophy, bone mineral disease causing
valvular and vascular calciﬁcation, inﬂammation, oxidative
stress, endothelial dysfunction, and sympathetic nervousCardiology Research and Practice 3
system hyperactivity [39]. Additionally, several epidemio-
logic studies point to a high prevalence of traditional and
non-traditional risk factors for CVD in patients with CKD
[35, 40–42]. Moreover, the prevalence and magnitude of
major risk factors for coronary heart disease increase as renal
failure progresses (e.g., hypertension, insulin resistance, and
hyperhomocysteinemia) [43].
The prevalence of left ventricular hypertrophy and
congestive heart failure is strikingly elevated in patients with
CKDstages2through5[44,45].Morbidityandmortalityfor
congestive heart failure and coronary heart disease are also
excessive in CKD [45–48]. For example, in the large Study of
Left Ventricular Dysfunction (SOLVD) Trial, moderate renal
impairment was associated with a 41% increased risk for
all-cause mortality, explained largely by heart failure, death
and hospitalization [49]. Even in acute coronary syndromes,
an estimated creatinine clearance less than 70mL/min was
associated with a 20% increase in mortality in both ST and
non-ST elevation myocardial infarction [50].
The close relationship between CVD and CKD may be a
manifestation of similar disease processes involved. Indeed,
cardiovascular and renal diseases have many types of mark-
ers in common, including: clinical, pathophysiologic (e.g.,
increased angiotensin II activity, upregulation of inﬂamma-
tory and ﬁbrosis producing cytokines), histopathologic (e.g.,
inﬂammatory inﬁltrates, vascular remodeling), biochemical
(e.g., c-reactive protein, homocysteine, lipoprotein (a) and
ﬁbrinogen), acute and chronic inﬂammation and subclinical
signs of atherosclerosis (e.g., increased common carotid
artery intima-media thickness) [51–59].
It is not surprising, then, that the MS, a constellation of
cardiovascularriskfactorswithwellestablishedimpactinthe
incidence of CVD and type II diabetes mellitus, might be
associated with the development and progression of CKD.
3. MetabolicSyndrome and
ChronicKidney Disease
3.1. Metabolic Syndrome as Risk Factor for Renal Disease. All
the components of the MS have individually been associated
withtheincidenceandprogressionofCKD.Themechanisms
and impact of hypertensive and diabetic injuries, the two
major etiologies of CKD in the world, have been well studied
and described [60–62]. Obesity has also been associated
with increased risk for ESRD in several epidemiological
studies [63, 64]. Dyslipidemia, in particular atherogenic
dyslipidemia (low HDL cholesterol, high triglycerides), has
also been shown to be an independent risk factor for
the development and progression of CKD in observational
studies and meta-analysis [42, 65–67].
The clustering of all these risk factors should identify
individuals at high risk for CKD. Over the last decade a
growing body of clinical evidence addressed this issue.
Several observational studies found that individuals with
the MS are at increased risk for presenting renal manifesta-
tions, namely, microalbuminuria and decreased glomerular
ﬁltration rate (GFR). In fact, epidemiologic studies have
linked the MS with an increased risk for microalbuminuria,
an early marker of glomerular injury and endothelial dys-
function [68–73]. A cross-sectional survey of nondiabetic
native Americans that was conducted by Hoehner et al.
[70] found that, after controlling for social, demographic,
and comorbidity factors, the patients with one to two and
those with three or more traits of the MS were 80% and
130% more likely to have microalbuminuria than those
without MS, respectively. Chen et al. [68]c o r r o b o r a t e d
these ﬁndings in another cross-sectional analysis with data
from 6125 individuals extracted from the National Health
and Nutrition Examination Survey (NHANES) III database-
the multivariate-adjusted odds ratio for microalbuminuria
in participants with the MS compared with participants
withoutMSwas1.89(1.34–2.67),andtheriskincreasedwith
the number of components of the MS.
Similarly, a number of observational studies evaluated
the association of MS and CKD (Table 2)[ 68, 73–81].
Almost all of them found a signiﬁcant association between
MS and CKD and consistently demonstrated an increased
risk parallel to the number of MS traits [68, 74, 77, 79].
However, the majority of the studies were cross-sectional
and,asso,unabletoestablishacause-and-eﬀectrelationship,
remaining unclear if the MS is a cause or a consequence of
the reduced kidney function. In fact, some reports suggest
that renal dysfunction perse, even in early stages, is a
cause of insulin resistance and MS which increases as the
nephropathy progresses [82, 83]. Additionally, experimental
work indicates that uremia is a cause of insulin resistance
rapidly reversible by peritoneal dialysis or hemodialysis,
further suggesting the presence of a low-molecular-weight
substance that functions as an insulin desensitizer in uremia
[84]. On the other hand, most of these studies included
patients with diabetes and hypertension, two known risk
factors for the development and progression of CKD, further
impairing the analysis.
In order to address the issues of causality and impact of
MS in the development of CKD, two relatively large longi-
tudinal studies, that excluded diabetic patients at baseline,
were published to date [74, 76]. Rashidi et al. showed an
88% (OR 1.88; 1.26–2.8) increased risk for CKD in patients
with MS compared to those without, after a 3-year followup
period [76]. However, when hypertensive patients at baseline
were excluded from the analysis the increased risk was wiped
out (OR 0.92; 0.446–1.917). Probably, the most signiﬁcant
study to date was published by Kurella et al., given its
large database and long followup period [74]. In this study,
the signiﬁcant association between the MS and subsequent
development of CKD was conﬁrmed (OR 1.43; 1.18–1.73).
Moreover, this association remained true after excluding
patients with hypertension at baseline (OR 1.46; 1.08–1.97)
and patients with incident hypertension or diabetes during
the followup (OR 1.24; 1.01–1.51), although with marginal
statistical signiﬁcance. However, even when hypertensive
patients were excluded at baseline, the patients with MS
had statistically signiﬁcant higher blood pressure within the
normal range (at baseline and at the end of followup) than
the ones without MS, making it impossible to exclude the
eﬀect of hypertension. Additionally, in this and other studies
[68, 73, 76] hypertension was the individual MS trait with4 Cardiology Research and Practice
Table 2: Studies that evaluated the association between the metabolic syndrome and chronic kidney disease.
Study Design Results
Chen et al.; Ann Intern Med
2004 [68]
Observational, cross-sectional N = 6217
American adults (database: NHANES III)
OR for CKD 2.60 (CI: 1.68–4.03)
OR for 2, 3, 4 or 5 traits of MS: 2.21 (CI: 1.16–4.24),
3.38 (C: 1.48–7.69), 4.23 (CI: 2.06–8.63), and 5.85 (CI:
3.11–11.0), respectively.
Kurella et al., JA mS o c
Nephrol 2005 [74]
Observational, longitudinal (followup 9yrs)
N = 10 096 nondiabetic, American adults
(database: ARIC Study)
OR for CKD 1.43 (CI: 1.18–1.73)
OR for CKD associated with 1, 2, 3, 4 or 5 traits of MS:
1.13 (CI: 0.89–1.45), 1.53 (CI: 1.18–1.98), 1.75 (CI:
1.32–2.33), 1.84 (95% CI, 1.27–2.67), and 2.45 (CI:
1.32–4.54), respectively.
OR for CKD (excluded pts with DM or HT during
followup) 1.24 (CI: 1.01–1.51)
Tanaka et al., Kidney Int
2006 [75]
Observational, cross-sectional N = 6980
Japanese adults
OR for CKD 1.54 (CI: 1.28–1.85)
Association only signiﬁcant for participants younger
than 60 y/o.
Rashidi et al., Clin J Am Soc
Nephrol 2007 [76]
Observational, longitudinal (followup 3yrs)
N = 4 607 non-diabetic (database: TLGS Study)
OR for CKD 1.88 (CI: 1.26–2.8)
OR for CKD (excluded pts with HT) 0.92 (CI:
0.446–1.917)
Chen et al., Nephrol Dial
Transplant 2007 [77]
Observational, cross-sectional N = 15160
chinese adults (database: inter-Asia study)
OR for CKD 1.64 (CI: 1.16–2.732)
OR for CKD associated with 1, 2, 3 and 4 + 5 traits of
MS: 1.51 (CI: 1.02–2.23), 1.50 (CI: 0.97–2.32), 2.13 (CI:
1.30–3.50), and 2.72 (CI: 1.50–4.93), respectively.
OR for CKD (excluded pts with HT) 1.74 (CI:
1.00–3.02)
OR for CKD (excluded pts with DM) 1.46 (CI:
1.02–2.07)
Zhang et al., Mayo Clin
Proc 2007 [73]
Observational, cross-sectional N = 2 310
chinese adults
OR for CKD 1.74 (CI: 1.32–2.30)
OR for CKD (excluded pts with HTor DM) 2.03 (CI:
1.05–3.94)
Kitiyakara et al., Kidney Int
2007 [78]
Observational, cross-sectional with a
longitudinal subgroup (followup 12yrs) N =
3195 Southeastern Asians (subgroup 2067)
OR for CKD 2.48 (CI: 1.33–4.62)-cross-sectional
OR for CKD 1.62 (CI: 1.00–2.61)-longitudinal
Association only signiﬁcant with the NCEP ATP III
criteria, not the IDF criteria
Luk et al., Diabetes Care
2008 [79]
Observational, longitudinal (Mean followup
4.6yrs) N = 5829 diabetic type II pts
(database: Hong Kong Diabetes Registry)
OR for CKD 1.31 (CI: 1.12–1.54)
OR for CKD associated with 2, 3, 4 or 5 traits of MS:
1.15 (0.83–1.60), 1.32 (0.94–1.86), 1.64 (1.17–2.32),
and 2.34 (1.54 –3.54), respectively.
Jang et al., J Public Health
2010 [80]
Observational, cross-sectional N = 5136
Korean adults (Database: KNHANES III) OR for CKD 1.77 (P < .05)
Yu et al., Nephrol Dial
Transplant 2010 [81]
Observational, cross-sectional N = 5911
Korean adults (Database: KNHANES III)
OR for CKD: NS
Association only signiﬁcant in men younger than 60y/o
and postmenopausal women.
ARIC: Atherosclerosis Risk in Communities; CI: Conﬁdence Interval; CKD: Chronic Kidney Disease; DM: Diabetes Mellitus; HT: Hypertension; IDF:
International Diabetes Federation; KNHANES: Korean National Health and Nutrition Examination Survey; MS: Metabolic Syndrome; NCEP ATP: National
Cholesterol Education Program Adult Treatment Panel; NHANES: National Health and Nutrition Examination Survey; NS: no signiﬁcance; OR: Odds Ratio;
TLGS: Tehran Lipid and Glucose Study.
the strongest association to CKD, even stronger than the
MS itself. The same consideration is valid for hyperglycemia
in some studies [68, 73, 77]. As Bakker et al. elegantly
demonstrated the problem with the concept of MS, as a way
to predict renal (and CVD) risk, is the dichotomization of
continuous variables and clustering correlated risk factors,
resulting in a signiﬁcant loss of predictive power [85].
A study of Kitiyakara et al. has even suggested that the risk
of CKD associated with the MS was diﬀerent accordingly to
the deﬁnition of MS used [78].
Although the results of these studies suggest there is
a close association between MS and renal disease, two
questions still do persist Does the MS add any relevant
additional information in terms of renal risk? Are there
speciﬁc pathophysiologic mechanisms of renal injury in the
MS? Kurella et al. also found that there were graded relations
among the number of MS traits, the Homeostasis Model
Assessment(HOMA)-insulinresistance,fastinginsulinlevels
and the risk for CKD, suggesting a pathophysiologic basis
for their ﬁndings [74]. Similar associations were previouslyCardiology Research and Practice 5
reported by Chen et al. [86]. These ﬁndings indicate that
that the MS directly contributes to the development of CKD
and the claimed pathophysiologic link is obesity, a hallmark
of the MS. Part of the explanation is, in fact, the link
between obesity, diabetes and hypertension [85]. However,
obesity (in particular visceral obesity) has independently
been associated with the risk of CKD and ESRD [63, 64,
68, 76, 87], even when corrected for these two indirect
mechanisms and proteinuria, suggesting the existence of
additional direct pathomechanisms.
3.2. Pathophysiology and Pathology of Renal Disease in
Metabolic Syndrome. Many studies evaluated the mecha-
nisms by which the factors in MS mediate pathological and
pathophysiological changes in the kidney. The underlying
mechanisms are still not completely understood but include
insulin resistance itself, inﬂammation, renal endothelial
dysfunction, oxidative stress, altered renal heamodynam-
ics, activation of the reninangiotensin-aldosterone system
(RAAS) and sympathetic nervous system (SNS), and dietary
factors.
3.2.1. Inﬂammation and Insulin Resistance. Inﬂammation
has been implicated in MS pathogenesis, especially as a
mechanism of insulin resistance and endothelial dysfunction
[88]. As mentioned, genetic and environmental factors
lead to central obesity. This enlarged mass of adipocytes
plays a vital role in the pathophysiology of MS. There
is increased ﬂux of free fatty acids into the liver leading
to excessive hepatic production of triglycerides and resul-
tant hypertriglyceridemia. Moreover, the adipocytes also
secrete inﬂammatory cytokines (e.g., MCP-1, TNF-α,I L -
6, leptin and C reactive protein), while there is relative
deﬁciency of the anti-inﬂammatory and antiatherogenic
cytokine adiponectin, resulting in a low-grade inﬂammatory
state thought to be responsible for insulin resistance and
endothelial dysfunction [89]. At the molecular level, the
linkbetweeninﬂammation andinsulinresistancehasalready
started to be elucidated [90–92], but is over the scope of this
article.
The role of chronic inﬂammation in renal pathophys-
iological changes in the setting of MS, driven both by
proinﬂammatory cytokines and adipocytokines, is not clear.
As stated, in obesity, the adipocyte-derived adiponectin, an
insulin-sensitizing anti-inﬂammatory protein, is decreased
along with an increase in the plasma levels of leptin.
Increased adipokines have been shown to directly contribute
to insulin resistance but their eﬀects on CKD have not
been examined. However, adipokines such as leptin can
cause renal vascular remodeling and disruption of renal
function. Some evidence indicates that leptin may represent
a link between obesity and increased sympathetic activity,
through its action on the hypothalamus, to increase blood
pressure [93]. It has also been shown that increased levels
of TNF-α promote generation of reactive oxygen species
(ROS) in glomerular cells and proximal tubular cells. These
ROS contribute to renal injury in several ways like induc-
ing renal endothelial dysfunction and microalbuminuria,
matrix accumulation, mesangial expansion, and ﬁbrosis [94,
95].
Within the kidney, insulin resistance and hyperinsuline-
mia associated with MS seem to induce local inﬂammation,
an important pathophysiological pathway for CKD. Insulin
may induce renal ﬁbrosis through stimulation of mesangial
cells and proximal tubule cells to produce TGF-b [96, 97].
Moreover, insulin stimulates the production of IGF-1 by
vascular smooth muscle cells and other cell types, which
has been implicated in the development of diabetic kidney
disease [98]. IGF-1 increases the activity of connective tissue
growth factor, a cytokine that has proﬁbrogenic actions on
renal tubular cells and interstitial ﬁbroblasts. In addition,
IGF-1 decreases the activity of matrix metalloproteinase-2,
an enzyme responsible for extracellular matrix degradation,
thereby promoting extracellular matrix expansion and renal
ﬁbrosis [99, 100]. Additionally, insulin resistance promotes
sodium and uric acid reabsorption, resulting in salt-sensitive
hypertension and hyperuricemia [88]. In the end, at the
glomerular level, insulin resistance and the release of inﬂam-
matory cytokines induce mesangial expansion, basement
membrane thickening, podocytopathy and loss of slit pore
diaphragm integrity, leading to the so-called “obesity-related
glomerulopathy” [89, 101]. This condition is characterized
by a speciﬁc histopathologic pattern of glomerulomegaly
(100% of cases), frequently accompanied by focal segmental
glomerulosclerosis (80% of cases), and has been repeatedly
described in obese patients without any other deﬁned pri-
mary or secondary glomerular diseases (including diabetic
nephropathy, hypertensive nephrosclerosis, and secondary
focal segmental glomerulosclerosis). This glomerulopathy
has pathologic features strikingly resembling the ones
inducedbydiabetesand/orhypertensionand,similarly,hasa
progressive clinical course. Of particular concern, the biopsy
incidence of this condition had a 10-fold increase over a
period of 15 years [101] and has been observed in children
as young as 3 years of age [101, 102].
3.2.2. Renal Haemodynamics. The consistent observation
of glomerulomegaly raised the hypothesis that glomerular
hyperﬁltration was a major mechanism in the pathogenesis
of obesity-related glomerulopathy. This was ﬁrst elucidated
in an animal model, the obese Zucker rat, which has hyper-
phagia due to a defect in the brain leptin receptor, resulting
in obesity and associated hyperglycemia, hyperinsulinaemia,
insulin resistance, dyslipidaemia and hypertension, thus
closely mimicking MS in humans. This model has glomeru-
lar hyperﬁltration and develops albuminuria, which progress
to renal failure with histological characteristics of glomeru-
lomegaly and focal and segmental glomerulosclerosis [103].
These ﬁndings have elegantly been conﬁrmed in humans by
Chagnac et al. [104, 105]. These authors demonstrated that
obese patients, with clinical characteristics consistent with
thediagnosisofMS,hada50%and30%increaseinGFRand
renal plasma ﬂow (RPF), respectively, as compared to lean
controls, resulting in increased ﬁltration fraction, an indirect
indicator of glomerular hypertension [104]. Moreover, when
17 morbidly obese patients who lost an average of 48kg6 Cardiology Research and Practice
at 1 year after bariatric surgery, postprandial GFR and
RPF were signiﬁcantly decreased and approached normal
levels, even though the patients were still obese [105]. In
a relatively recent study with young (mean age 18 years)
healthy males, MS was associated with a 6.9-fold increase
in the OR of glomerular hyperﬁltration [106]. The authors
concluded that glomerular hyperﬁltration has an early-onset
in life, before any manifestations of CVD, and so may be a
markerofmetabolicrisk.Itiswellknownthathyperﬁltration
(even in nondiabetic patients) leads to albuminuria (a well
established cardiovascular and renal risk factor), which is
consistent with the aforementioned epidemiologic studies
that showed a graded prevalence of microalbuminuria
according to the number of MS traits [68–73]. Besides the
known eﬀect of hyperglycemia, these renal haemodynamic
changes have been attributed in experimental studies to
a higher intake of dietary protein in these individuals
[107–109]. The amino acid excess induces a proﬁbrotic
and proliferative mesangial injury response, mediated by
increased formation of advanced glycation end-products,
presumably the result of greater availability of free amino
groups for glycation reactions [110, 111].
3.2.3. Oxidative Stress. The presence of renal oxidative stress
has been documented in animal models of insulin resistance,
diabeticpatients,andpatientswithCKDofvariousetiologies
[112, 113].
High glucose and free fatty acid increase mitochondrial
ROSinrenalendothelialcells,whichmaycontributetotissue
dysfunction by dysregulation of redox-sensitive signaling
pathways or by oxidative damage to biological structures
(DNA, proteins, lipids, etc.) [114].
Lipid peroxidation, a well-known consequence of exces-
sive ROS, is the ﬁrst step in the generation of oxidized
LDL, which accumulates in renal mesangial cells and form
foam cells [115]. Lipid peroxidation also induces endothelial
damage and inﬂammatory response, impairs vasodilatation
and activates macrophages [116, 117]. Lipid peroxidation
itselfgeneratesmorefreeradicalsandROStherebyincreasing
the potential for renal injury.
Additionally,theaforementionedglomerularhyperﬁltra-
tion may also be caused by mitochondrial ROS, through the
activation of cyclooxygenase-2 gene transcription followed
by prostaglandin E2 overproduction and preglomerular
vasodilation [114]. Furthermore, excessive oxidative stress
stimulates the synthesis of angiotensin II (via the nuclear
factor-kB pathway), which further increases glomerular
hypertensionandhyperﬁltrationbycausingeﬀerentarteriole
vasoconstriction. Angiotensin II also stimulates the synthesis
of TGF-b, thereby promoting glomerular ﬁbrosis [118].
Moreover, ROS-dependent b-cell damage is thought to
be involved in the progression from MS to type II diabetes
mellitus [119] and ROSs enhance the formation of advanced
glycationendproducts[120],whichhaveamajorpathophys-
iologic role in the development of diabetic nephropathy.
3.2.4. Endothelial Dysfunction. Dysfunction of the vascular
endothelium is an important factor in the pathogenesis of
diabetic nephropathy and has its clinical counterpart in
microalbuminuria [121, 122].
Available evidence indicates that the insulin-receptor sig-
naling pathway mediating glucose uptake in vascular en-
dothelium requires stimulation of endothelial nitric oxide
(NO) synthase and subsequent NO production [123], a
potent vasodilatory and antithrombotic substance. Com-
parable endothelial responses—enhanced NO production
with vasodilation—are induced by adiponectin [124]. These
actions mediate a hemodynamic component of energy dis-
tribution, enhancing tissue blood ﬂow to optimize nutrient
delivery. In insulin-resistant states, such as obesity, MS and
type 2 diabetes mellitus, insulin- (and adiponectin-) induced
NO production and endothelium-dependent vasodilatation
areimpaired,representingoneofseveralmechanismslinking
abdominalobesity/insulinresistanceandhypertension[125–
127].Additionally,excessiveoxidativestressfurtherdecreases
NO production and availability thereby contributing to
endothelial dysfunction in diabetic and MS patients [120].
Another product of endothelial cells, endothelin-1, has
been implicated in CVD, hypertension and several kidney
diseases. Insulin stimulates the secretion of endothelin 1
fromglomerularendothelial,mesangialandvascularsmooth
muscle cells through the insulin receptor. Endothelin-1 is
associated with severe intrarenal vasoconstriction, reduced
GFR, mesangial cell contraction and proliferation and
sodium and water retention [128–130]. Patients with the
MS are hyperinsulinemic, suggesting that endothelin-1 may
be involved in the development of nephropathy in these
patients.
3.2.5. Fructose. Recently, another dietary factor-fructose-
has been implicated in the pathophysiology of MS, and
could establish the link between modern dietary patterns,
systemic inﬂammation, MS and cardiovascular and renal
disease progression [131]. Fructose is a simple sugar that
is a component of table sugar as well as of high fruc-
tose corn syrup, which is a universally used sweetener.
Fructose consumption has increased markedly worldwide
during the last several decades, which correlates closely
with the increasing incidence of obesity and MS [132]. The
administration of fructose to both animals and humans
has been showed to induce most of the features of MS
[133, 134]. This is clinically relevant as some studies have
reported that adolescents can easily ingest 15%–20% of
their energy intake as fructose [135]. In recent years,
experimental evidence associating fructose and systemic
inﬂammation has accumulated, pointing out an increased
expression of leukocyte adhesion proteins (ICAM-1) and
chemokines (MCP-1) in various cell types (endothelial,
proximal tubular, and vascular smooth muscle cells) [131].
Theunderlyingmechanismappearstoberelatedtoincreased
uric acid generation and resulting hyperuricemia. Uric acid
hasbeenshowntoinduceoxidativestress,reducenitricoxide
generation, stimulate the local renin-angiotensin system and
induceexpressionofproinﬂammatorychemokines,resulting
in a signiﬁcant increase in renal injury and inﬂammation
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may represent new treatment opportunities (e.g., reduction
ofdietaryfructose,uricacidloweringagentsor,inthefuture,
blocking the signaling pathways driving the response), as
there is increasing evidence that systemic inﬂammation may
increase the risk of cardiovascular outcomes and progression
of renal disease [140–142].
3.2.6. Sympathetic Nervous System and Renin-Angiotensin-
Aldosterone System. Finally, the sympathetic nervous system
(SNS)andtherenin-angiotensin-aldosteronesystem(RAAS)
are considered important pathophysiologic factors in the
development of MS, which can also contribute to the high
cardiovascular risk associated with it. Some studies have
associated plasma aldosterone levels with insulin resistance
and MS, in both normotensive and hypertensive patients
[143–145]. Angiotensin II is thought to have a role in
the development of insulin resistance by inducing oxidative
stress and also in the development of salt-sensitive hyper-
tension by promoting sodium reabsorption, which could
explain the beneﬁts of blocking the RAAS on prevention of
new cases of diabetes [146].
In summary, apart from the eﬀect of hypertension and
diabetes, there are other contributing factors for develop-
ment of kidney injury in MS. These include oxidative stress
and systemic inﬂammation (probably induced by dietary
factors like fructose and adipose tissue-derived cytokines),
endothelial dysfunction, altered renal hemodynamics (par-
tially as the result of high dietary protein intake), excessive
renal sodium reabsorption, activation of the RAAS and SNS,
atherogenic lipid proﬁle, and even physical compression of
the kidneys by adipose tissue. Complex interactions between
allthesefactorsultimatelyleadtoglomerularhyperﬁltration,
glomerular cell proliferation, matrix accumulation, and,
ﬁnally, glomerulosclerosis and progressive loss of nephrons.
3.3. Prevention of Renal Disease in Metabolic Syndrome. The
association between MS and renal disease raises the question
whether treating the components of the syndrome could
prevent renal injury. Interventional randomized controlled
trials addressing renal endpoints in the speciﬁc setting
of MS have not been published to date. However, each
diagnostic criterion of MS identiﬁes a risk factor for CVD
that requires intervention independently of its contribution
to CKD incidence or progression. Although the value of
a multifactorial intervention for preventing cardiovascular
events and CKD in the setting of MS has not been examined,
ithasalreadybeenproposed[147].Accordingtothisstrategy,
upon the diagnosis of MS, clinicians should implement
a multitargeted intervention with treatment goals based
on global CVD risk assessment (using, e.g., the 10-year
Framingham risk score or the European risk SCORE chart
andtheestimatedGFR).Thismultidimensionalintervention
should focus simultaneously on life-style changes, glycemic
and blood pressure control, lipid lowering, and other proven
beneﬁcial treatments, like antiplatelet therapy (Figure 1).
The value of simultaneous management of multiple risk
factors has been tested in type II diabetic patients (a group
forwhichMSisintendedtobeahighriskfactor),resultingin
a lower risk of CVD and nephropathy in the intensive treat-
ment group (stepwise implementation of behavior modiﬁca-
tion and pharmacologic therapy with strict treatment targets
for hyperglycemia, hypertension, dyslipidemia, and microal-
buminuria, plus secondary prevention of cardiovascular dis-
easewithaspirin;treatmentoverseenbyaprojectteam)com-
pared to conventional treatment (treatment for multiple risk
factors from their general practitioner, according to current
recommendations, with the possibility of being referred to
specialists) [148]. Moreover, it has been shown in this group
of patients that intensive blood pressure (<130/80mmHg)
and blood glucose control (aiming at glycated hemoglobin
level 6.5%) eﬀectively prevent cardiovascular events, the
development of microalbuminuria, and overt nephropathy
[149, 150]. Despite that, the Action to Control Cardiovas-
cular Risk in Diabetes Study Group (ACCORD) trials alert
us that treating diabetic patients to normal values (systolic
blood pressure <120 and glycated hemoglobin level 6.0%)
may not be beneﬁcial and increase the risk of adverse events
[151,152].Thesestudiesreinforcethenotionthataggressive,
although cautious, multitargeted management of the MS
may confer protection for CVD and CKD [147]. In fact,
several lines of evidence indicate that interventions directed
at each component of the MS can protect the kidney.
3.3.1. Therapeutic Lifestyle Changes. Lifestyle modiﬁcations,
including physical activity and dietary interventions, with
the objective of weight loss are a cornerstone of therapy
[1]. Physical activity and weight reduction improve insulin
resistance even in people with renal impairment and ESRD
[153]. Small weight reductions have been shown to have
signiﬁcant beneﬁcial eﬀects. A weight loss of 5%–10%
of initial body weight has lowered the risk for diabetes
and CVD, as well as signiﬁcant (P = .001) improvements
in related modiﬁable risk factors, including HbA1c, HDL
cholesterol, triglycerides, and systolic and diastolic blood
pressure [154].
Beneﬁcial renal eﬀects, like reduction of glomerular
hyperﬁltration and albuminuria, have been demonstrated
after weight loss (either through diet or bariatric surgery)
[105, 155], although these results still need to be demon-
strated by properly designed clinical trials. Additionally, the
impact on renal outcomes resulting from improved insulin
resistance through pharmacologic weight loss [156] or the
Mediterranean diet [157] has not been studied. Moreover,
in light of what is known about renal hemodynamics (see
above), the safety of the so popular “high-protein low-
carbohydrate”weight reduction diet should alsobe analyzed.
Finally, the potential eﬀects of dietary fructose reduction
in the incidence of MS and its renal and cardiovascular
consequences represent an exciting ﬁeld of research in the
near future.
We strongly believe that a reasonable goal for obese
patients with the MS would be a weight loss of 5–10%
of body weight, through an eﬀective ongoing program
that includes an increase in physical activity to at least
150min/week of moderate exercise, similar to the recom-
mendations for prevention of type II diabetes mellitus in8 Cardiology Research and Practice
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-Increase physical
activity
-Drug treatment?∗
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(especially ACE
inhibitors, and ARBs)
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(especially statins)
-Low dose aspirin
(for high CVD
risk subjects)
Figure 1: Management of the metabolic syndrome [147] (reproduced with permission). ACE: angiotensin converting enzyme; ARBs:
angiotensin II receptor antagonists; CVD: cardiovascular disease; GFR: glomerular ﬁltration rate; MS: metabolic syndrome; OGTT: oral
glucose tolerance test.
patients with impaired glucose tolerance (IGT) or impaired
fasting glucose (IFG) [158].
3.3.2. Blood Pressure Control. As mentioned, intensive treat-
ment of diabetes and hypertension has been shown to
improve renal outcomes in diabetic patients. Moreover,
blocking the RAAS is extensively recommended as ﬁrst-
line anti-hypertensive therapy for renal and cardiovascular
protection, especially in diabetic and/or proteinuric patients
[159, 160]. Given the aforementioned role of RAAS activa-
tion in the pathophysiology of the MS and the importance
of hypertension on CKD risk in the setting of MS, we should
expect great impact of RAAS blockers on the development
of kidney injury. This, however, has never been studied.
Nevertheless, angiotensin-converting enzyme inhibitors and
angiotensinreceptorblockersshouldbethepreferredantihy-
pertensivedrugsinpatientswithMSasindiabetics[161].On
the other hand, the use of thyazide diuretics and b-blockers
should be avoided (or restricted to treatment of resistant
hypertension) in patients with MS due to the risk of new-
onset diabetes [162].
The therapeutic goal should be established according
to the global cardiovascular risk, as recommended by the
latest guidelines [162]. In general, given that the MS is a
constellation of CVD risk factors (implying the presence
of at least two traits) and often with subclinical organ
damage, a blood pressure lower than 130/80mmHg should
be attained in most patients [162]. Probably, for renal
p r o t e c t i o n ,al o w e rt a r g e t( <120/75mmHg) is beneﬁcial
in highly proteinuric patients (>1gr/day) [163]. However,Cardiology Research and Practice 9
as mentioned before, bringing systolic blood pressure to
normal values (<120mmHg) may increase treatment side-
eﬀects without additional beneﬁt, especially in patients with
advanced atherosclerotic disease [152].
3.3.3. Glycemic Control. Given the known impact of diabetes
in the development and progression of CKD, glycemic
controlindiabeticpatientsorpreventing/delayingnew-onset
type II diabetes mellitus is a main goal of therapy in patients
with MS. The use of agents that improve insulin sensitivity,
like metformin or thiazolidenidiones, is of great interest
but also raises some concerns. Metformin has been shown
to reduce the incidence of both type II diabetes mellitus
a n dM Si ns u b j e c t sw i t hI G T .H o w e v e r ,m e t f o r m i nw a s
less eﬀective than intensive lifestyle modiﬁcation (regular
physical activity and low-fat diet) [164, 165]. Despite its
beneﬁcial eﬀects, metformin is contraindicated in CKD
patients with creatinine clearance lower than 60mL/min
due to the risk of severe lactic acidosis. Thiazolidenid-
iones(peroxisomeproliferatoractivatorreceptor-γ agonists),
another class of antidiabetic agents with insulin sensitizing
properties, have multiple pleotropic eﬀects that, in theory,
are of great interest in the setting of MS. They reduce blood
pressure and modulate dyslipidaemia, inﬂammation, oxida-
tive stress, endothelial dysfunction, ﬁbrosis and remodelling,
and glomerular cell proliferation, and reduce urine albumin
excretion [166]. Moreover, thiazolidenidiones also reduce
the incidence of type II diabetes mellitus in prediabetic
subjects [167]. However, their use causes weight gain and
ﬂuid retention, an undesirable eﬀect especially for obese
subjects and some drugs of this class have been associ-
ated with an increased incidence of myocardial infarction
[168].
Other classes of antidiabetic drugs have been shown
to improve cardiovascular risk proﬁle in diabetic and pre-
diabetic patients, beyond glycemic control [169]. Drugs that
promoteweightloss,improvecontrolofothercardiovascular
risk factors (like blood pressure and lipid proﬁle) or that
produce beneﬁcial eﬀects in surrogate markers of subclinical
atherosclerosis, are very attractive in the setting of MS. For
example, in a systematic review, the old alpha-glucosidase
inhibitors have been shown to produce a modest weight
reduction (−1.2Kg) as well as improvements in total choles-
terol, LDL cholesterol, triglycerides, systolic and diastolic
blood pressure in patients with IGT and/or IFG [170].
Additionally, in the same group of patients, acarbose was
associated with a signiﬁcant reduction in the progression of
carotid intima-media tickness (IMT) compared to placebo-
the annual progression of IMT was reduced by 50%, with
a mean followup of 3.9 years [171]. More importantly,
in the Study to Prevent Non-Insulin-Dependent Mellitus
(STOP-NIDDM), also in patients with IGT, acarbose was
found to reduce the risk of developing any cardiovascular
event by 49% with an absolute risk reduction of 2.5%
[172].
On the opposite time-line end, also the new incretin
mimetics—Glucagon-like peptide-1 (GLP-1) receptor ago-
nists and Dipeptidyl peptidase-4 (DPP-4) inhibitors-have
beneﬁcial pleotropic eﬀects on various MS traits. GLP-
1 receptor agonists are associated with progressive, dose-
dependent weight loss in patients with type 2 diabetes [173]
while the DPP-4 inhibitors are generally considered weight
neutral [169]. Exenatide, a GLP-1 receptor agonist, has been
shown to produce signiﬁcant reductions in total cholesterol,
triglycerides, systolic and diastolic blood pressure in patients
with type II diabetes mellitus with the MS [174]. The eﬀect
on blood pressure, a major determinant of renal and cardio-
vascular risk in patients with MS, is very signiﬁcant and is
greater in patients with systolic blood pressure >130mmHg
(−11.4mmHg and −3.6mmHg for systolic and diastolic
blood pressure, resp.; P < .05) [175]. Similarly, DPP-4
inhibitors also produced favorable trends on lipid levels and
systolicanddiastolicbloodpressure,eveninpatientswithout
diabetes [173, 176]. Moreover, GLP-1 receptor agonists
wererecentlyassociatedwithimprovementsininﬂammatory
state,insulinresistanceandbeta-cellfunctionascomparedto
sulfonylureas in patients with type II diabetes [177].
At the present time, there are no data on glycemic
control goals in patients with MS who are not diabetic.
Both for renal and CVD prevention the obvious treatment
goal is to prevent the onset of overt type II diabetes in
this group of patients. Current recommendations are to
treat patients with IFG, IGT or glycated hemoglobin of
5.7%–6.4% though weight loss and physical activity [158].
Despite their beneﬁcial eﬀects, the use of antidiabetic drugs
is actually not recommended in prediabetic subjects [178],
maybe with the exception of metformin for patients at very
highrisk of developing diabetes (combined IFG and IGT
plus other risk factors such as glycated hemoglobin >6%,
hypertension, low HDL cholesterol, elevated triglycerides, or
family history of diabetes in a ﬁrst-degree relative) who are
o b e s ea n du n d e r6 0y e a r so fa g e[ 158].
For patients with overt type II diabetes mellitus, both
for prevention of nephropathy and CVD risk reduction,
the recommended goal is to achieve a glycated hemoglobin
<7%, although the available evidence is more compelling for
microvasculardiseaseprevention[158].Moreover,datafrom
large diabetes trials suggest a small but incremental beneﬁt
in microvascular outcomes with glycated hemoglobin closer
to normal [150, 158, 179]. Therefore, despite the results
of the aforementioned ACCORD trial, for renal disease
prevention a lower glycated hemoglobin might be pursued
in selected patients (those with short duration of diabetes,
long life expectancy, and no signiﬁcant CVD), with close
monitoring for hypoglycemia and other adverse eﬀects of
treatment [158]. In the setting of MS, the antidiabetic drugs
with insulin sensitizing properties and/or with beneﬁcial
eﬀects on other cardiovascular risk factors/markers should
be considered for ﬁrst-line therapy.
3.3.4. Dyslipidaemia Correction. Statins are the most widely
used agents for dyslipidemia, but their role in the MS
has not been well evaluated. Nevertheless, for example, in
the Scandinavian Simvastatin Survival Study (4S), among
patients with elevated serum LDL-cholesterol and estab-
lished coronary disease, those with characteristics of the MS10 Cardiology Research and Practice
had both the highest risk of major coronary events and
the greatest beneﬁt from statin therapy [180]. Additionally,
treatment of patients with known coronary disease and the
MS with atorvastatin (80mg/day), compared to atorvastatin
(10mg/day), decreased the rate of major cardiovascular
events [181]. The eﬀect of statins on kidney function
has been addressed in several clinical studies and meta-
analysis. It was demonstrated that statins reduce kidney
function loss in CKD patients and reduce albuminuria
in microalbuminuric and macroalbuminuric patients [182,
183]. Moreover, statins have been shown to slow down GFR
decline in high cardiovascular risk patients with normal or
near normal renal function at baseline and the patients with
MS were the ones with the greatest beneﬁt [184]. The role
of statins for renal protection is attributed to their presumed
pleiotropic eﬀects including anti-inﬂammatory, antiﬁbrotic,
antihypertensive, and antioxidant properties.
Fibrates are hypolipidaemic drugs very eﬀective in
reducing triglycerides, a major feature of MS. Some studies
have suggested an improvement in proteinuria progression
on diabetic patients treated with ﬁbrates [185], but their role
in preventing CKD in MS patients is still unknown.
For CVD prevention (and probably also for renal disease
prevention and/or progression), the goal of therapy for MS
patients, as for diabetic patients, should focus primarily in
LDL cholesterol. In most cases, patients with MS represent
a group with very high added risk for CVD (Framingham
10 year risk >20%), even if they are not diabetic. As so,
most patients with MS and all patients with type II diabetes
mellitus (a coronary heart disease equivalent) should be
treated to a primary treatment goal of LDL cholesterol
<100mg/dL. In patients with overt CVD, a lower target of
<70mg/dL may be considered [158]. For patients with lower
CVD risk (Framingham 10 year risk 10%–20%), a target of
<130mg/dLisconsideredadequate[9].Secondarytreatment
goals, in this population are triglycerides <150mg/dL and
HDL cholesterol >40mg/dL in men and >50mg/dL in
women. To achieve these goals therapeutic lifestyle changes
(with emphasis on weight loss and physical activity) should
be implemented, but statin therapy will almost always be
necessary and should be started simultaneously with lifestyle
changes in high risk patients [9, 158].
4. Conclusions
The existence of MS as a unique pathophysiologic process
andwhetheritconfersriskbeyonditsindividualcomponents
have been questioned and are still under debate. Moreover,
other clinical variables and risk scores have been proven
superior to MS in indentifying individuals at risk for type
II diabetes mellitus or CVD [186, 187].
Despite that, in the last decade, a growing body of epi-
demiologic evidence has associated the MS with the risk
for developing renal damage, clinically expressed in the
formofmicroalbuminuriaand/orCKD.Giventheadditional
association between MS and CVD risk, which can be
further aggravated if renal impairment is superimposed, MS
represents, at least, a powerful awareness tool for the need
to aggressively prevent and manage risk factors. This need
is underscored by the epidemic of obesity in the developed
world, particularly aﬀecting adolescents and young adults,
which can pose in the future a huge burden on the health
care system including dialysis facilities [85].
The association between MS and renal damage is,
in part, explained by hypertension and impaired glucose
metabolism. However, experimental and epidemiologic data
suggest that other aspects of the MS are associated with
the development of renal abnormalities and should also
deserve close attention as they are modiﬁable risk factors. In
particular, prevention of obesity and promotion of healthy
lifestyles are likely to be the most eﬀective approaches and
should be a public health priority.
An increasing body of evidence suggests that treating
each component included in the MS deﬁnition can improve
renal outcomes. However, it has never been investigated
whether treating patients with MS will prevent the devel-
opment and progression of CKD. Clinical trials, in the
setting of MS, to verify whether treating its components may
eﬀectively prevent renal impairment should be a priority.
These should include trials of weight loss and nutritional
strategies (e.g., low protein and low fructose diets) and
multitargeted treatment of risk factors (blood pressure and
glycemic control, renin-angiotensin system inhibition, lipid
lowering and insulin resistance). Finally, the new insights
intothepathophysiologyofsystemicinﬂammationintheMS
can provide, in the future, new treatment targets.
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